Halozyme Therapeutics Inc. Common Stock vs Republic Services Inc. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $117.12 (market cap $12.44B), while Republic Services Inc. Common Stock trades at $225.58 (market cap $67.34B). The key difference: Republic Services Inc. Common Stock is far larger — about 5.4× Halozyme Therapeutics Inc. Common Stock's market cap, and Republic Services Inc. Common Stock pays a 1.22% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| HALO | RSG | |
|---|---|---|
Market Cap | $12.44B | $67.34B |
Volume | 1,772,623 | 955,255 |
Sector | Health | Industrials |
52-Week High | $116.82 | $232.27 |
52-Week Low | $61.63 | $197.73 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $14.36B | $81.53B |
Dividend Yield | — | 1.22% |
Signals from Pluang's Aura AI — not financial advice
Halozyme Therapeutics (HALO) trades at $109.62, down 1.31% today but near its recent highs. The stock shows strong fundamental momentum with revenue growth from $1.4B in 2025 to $1.7B projected for 2026 and net income margins improving to 24.85%. Recent positive developments include a patent win against Merck in Europe and an expanded collaboration with argenx, enhancing its ENHANZE technology revenue streams. Technical indicators are bullish on moving averages, though oscillators signal neutrality with RSI at 73 suggesting overbought conditions. Support is firm at $107 with resistance at $112.
HALO presents a growth opportunity driven by robust financials and strategic expansions, but risks include high valuation multiples (P/E 32.15, P/B 86.68) and insider selling by the CEO. Analyst consensus is strongly bullish with 66.7% buy ratings and a $106 price target, though the current price exceeds this, indicating potential near-term consolidation. Investors should weigh solid earnings beats against elevated expectations and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →